昂利康(002940) - 2023 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2023 was ¥343,692,067.75, a decrease of 4.35% compared to the same period last year, while year-to-date revenue increased by 11.65% to ¥1,186,981,982.04[4] - Net profit attributable to shareholders for Q3 2023 was ¥5,565,125.25, down 80.92% year-on-year, with year-to-date net profit increasing by 1.40% to ¥109,793,786.06[4] - The basic earnings per share for Q3 2023 was ¥0.03, a decline of 90.32% compared to the same period last year, while year-to-date earnings per share remained unchanged at ¥0.54[4] - Total revenue for the period reached ¥1,186,981,982.04, an increase of approximately 11.6% compared to ¥1,063,113,569.06 in the previous period[24] - The net profit for the period was ¥140,889,451.62, representing a growth of approximately 24.2% from ¥113,440,888.00 in the previous period[24] - The net profit attributable to the parent company for Q3 2023 is CNY 109,793,786.06, a slight increase from CNY 108,275,724.51 in Q3 2022, representing a growth of 1.4%[25] - The total comprehensive income for the period was CNY 140,889,451.62, compared to CNY 113,440,888.00 in the previous year, representing an increase of 23.9%[25] Assets and Liabilities - Total assets as of September 30, 2023, reached ¥3,207,490,489.72, representing a 23.55% increase from the end of the previous year[4] - The total assets of the company reached ¥3,207,490,489.72, up from ¥2,596,083,285.56, reflecting a growth of about 23.5%[22][23] - The company’s total liabilities increased to ¥1,395,747,370.71 from ¥949,926,896.44, reflecting a growth of approximately 47.0%[22] Cash Flow - Cash flow from operating activities for the year-to-date period was ¥316,232,297.03, an increase of 47.81%, demonstrating improved cash generation capabilities[4] - The net cash flow from operating activities for the first nine months of 2023 was ¥316,232,297.03, an increase of 47.73% compared to ¥213,947,191.32 in the same period of 2022, primarily due to increased government subsidies and the consolidation of Keri Bio[11] - The net cash flow from investing activities improved by 66.30%, from -¥499,843,082.65 in 2022 to -¥168,426,925.72 in 2023, mainly due to a reduction in external investments[11] - The net cash flow from financing activities decreased by 48.22%, from ¥200,579,871.01 in 2022 to ¥103,851,973.32 in 2023, attributed to increased cash payments for dividends and debt repayment[11] - The cash inflow from operating activities totaled CNY 1,357,665,419.15, slightly up from CNY 1,339,368,669.84 in the previous year, showing a growth of 1.9%[26] - The cash outflow from investing activities was CNY 309,782,369.92, a decrease from CNY 683,381,907.06 in the previous year, indicating a reduction of 54.7%[27] - The cash flow from financing activities generated a net inflow of CNY 103,851,973.32, down from CNY 200,579,871.01 in the previous year, reflecting a decline of 48.2%[27] Research and Development - The company’s R&D expenses for the first nine months of 2023 were ¥98,546,084.85, an increase of 48.23% compared to the same period last year, indicating a focus on innovation[10] - Research and development expenses for the period were ¥98,546,084.85, compared to ¥66,481,632.41 in the previous period, indicating an increase of about 48.2%[24] Inventory and Operating Costs - The company reported a significant increase in inventory, which rose by 63.89% to ¥480,569,864.61, attributed to increased raw material stocking and the consolidation of Keri Bio[8] - The total operating costs amounted to ¥1,063,383,350.81, up from ¥947,916,572.58, reflecting a rise in operating costs by about 12.2%[24] - Inventory levels rose significantly to ¥480,569,864.61 from ¥293,229,091.22, indicating an increase of approximately 63.9%[21] Financing and Borrowings - The company’s long-term borrowings increased by 213.83% to ¥470,750,000.00, reflecting a strategy to leverage financing for growth[9] - The company's long-term borrowings increased to ¥470,750,000.00 from ¥150,000,000.00, showing a substantial rise of approximately 213.2%[22] Shareholder Information - As of the end of the reporting period, the total number of ordinary shareholders was 11,365, with the largest shareholder, Shenzhou Juntai Investment Co., holding 35.44% of shares[13] - The company acquired an additional 1.39% stake in Keri Bio for ¥6,975,500, increasing its total ownership to 63.09%[15] - The company has initiated a share repurchase plan, having repurchased 138,000 shares, representing 0.07% of the total share capital, with a total transaction amount of ¥2,652,473.30[16] Legal and Technical Developments - The company is involved in ongoing litigation regarding patent rights related to its generic drug applications for sacubitril/valsartan sodium tablets[17] - The company signed a technical development contract with Beijing Sunshine Nuohua Pharmaceutical Research Co., Ltd. for the NHKC-1 project[15] - The company revised its shareholder agreement concerning Hunan New He New Pharmaceutical Co., Ltd., updating governance and investment rights[16] - As of September 30, 2023, the company has two ongoing patent dispute cases regarding the sacubitril/valsartan sodium tablets (200mg and 100mg) filed by Novartis, which are still under review and will not significantly impact current or future profits[18][19] Audit Status - The company has not undergone an audit for the Q3 report[28]